ISRG Intuitive Surgical (NASDAQ) pre-market $499.53 on 20 Feb 2026: AI-enabled devices guide outlook

ISRG stock opens pre-market at $499.53 on 20 Feb 2026, down 0.25% from yesterday as traders weigh growth versus valuation. Intuitive Surgical, Inc. (ISRG) on NASDAQ remains a leader in robotic-assisted surgery, with a market cap of $177.40B and trailing EPS of 7.87. The stock trades below its 50-day average ($542.29) and 200-day average ($515.97), keeping momentum cautious. Investors focused on AI-driven procedure adoption and device launches will find the next earnings date, 21 Apr 2026, a key catalyst for ISRG stock moves

ISRG stock: Pre-market price, volume and immediate drivers

Pre-market ISRG stock sits at $499.53, after a -$1.23 change and a -0.25% intraday move. Today’s range shows a low of $495.25 and high of $503.73, with volume running at 1,432,330 shares versus an average of 1,919,676. The stock opened at $495.71 and closed previously at $500.76. Market-watchers point to recent institutional filing activity and sector rotation within Healthcare as short-term drivers. For up-to-the-minute quotes consult MarketWatch and our ISRG page at Meyka AI.

ISRG stock earnings and fundamentals

Intuitive Surgical reports trailing EPS of 7.87 and a P/E of 63.47, reflecting premium valuation tied to growth expectations. Key fundamentals: revenue per share 28.36, free cash flow per share 7.02, book value per share 50.55, and cash per share 16.72. Profit margins remain strong with net margin 28.38% and operating margin 29.27%. R&D intensity is meaningful at 13.03% of revenue, supporting the Ion platform and digital services expansion. These metrics frame ISRG stock valuation against future procedure growth.

ISRG stock technicals and trading context

Technically, ISRG stock shows RSI 43.90 indicating neutral momentum and ADX 37.21 signaling a strong trend context. Price sits under the 50-day moving average $542.29 and under the 200-day average $515.97, with Bollinger Bands middle at $501.12. MACD histogram reads 2.27, suggesting short-term bullish divergence despite recent downside. Average true range is 13.65, and on-balance volume is negative, indicating distribution. Traders should note the stock’s relative underperformance YTD -11.11% and one-year change -17.91% in sector rotation periods.

Meyka AI rates ISRG with a score out of 100 and forecast

Meyka AI rates ISRG with a score out of 100: 79.61 out of 100 — Grade B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month price of $604.32, implying an upside of +20.99% versus the current $499.53. Shorter-term model outputs show a monthly projection of $424.33 (-15.06% downside) and a quarterly projection of $514.64 (+3.03%). Forecasts are model-based projections and not guarantees.

ISRG stock risks and opportunities in AI-driven healthcare

Opportunities: adoption of robotic-assisted procedures, expansion of the Ion endoluminal platform, and growing digital services that can lift recurring revenue. Risks: high valuation (P/E 63.47), single-vendor exposure in instrumentation, and competitive entrants in surgical automation. Recent insider and fund filings show modest position shifts, and analyst coverage remains tilted toward buys (16 buys, 4 holds, 2 sells). See recent filings and coverage at MarketBeat. Consider sector performance in Healthcare and Medical Instruments when sizing positions.

ISRG stock price targets, analyst view and portfolio fit

Analyst consensus leans positive with a neutral consensus score of 3.00 driven by 16 buy, 4 hold and 2 sell ratings. Meyka’s near-term technical price target is $515.00, while the 12-month model target is $604.32 and a 3-year projection sits at $731.31. Given a market cap of $177.40B and cash-rich balance sheet, ISRG stock can fit growth allocations focused on AI-enabled healthcare technology but may require trimming during valuation spikes.

Final Thoughts

ISRG stock opens pre-market at $499.53 on 20 Feb 2026 with mixed signals: strong fundamentals and growth prospects but premium valuation. Intuitive Surgical benefits from durable margins, a cash-rich balance sheet, and meaningful R&D spend that supports the da Vinci and Ion franchises. Technicals show neutral momentum with price below the 50-day average, which raises near-term caution. Meyka AI’s forecast model projects a 12-month price of $604.32, an implied upside of +20.99% from today’s price, while a monthly stress scenario shows $424.33 (-15.06%). Our proprietary grade of 79.61 (B+, BUY) reflects relative strength versus peers, revenue and cash flow growth, and analyst positioning. Investors should weigh the long-term AI and robotics opportunity against the high P/E of 63.47 and potential short-term volatility. Use position sizing and stop rules if allocating to ISRG stock, and watch the next earnings release on 21 Apr 2026 as a key catalyst. Meyka AI provides this as data-driven market analysis and not as financial advice; model outputs are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.